Horizon Therapeutics plc Highlights Expanding R&D Efforts with Data Presentations at the EULAR European Congress of RheumatologyBusiness Wire • 05/21/21
Horizon Therapeutics plc Named One of the 2021 Best Workplaces in Chicago™ by Great Place to Work®Business Wire • 05/20/21
Horizon Therapeutics plc Ranked #1 in Overall Corporate Reputation Among U.S. Patient Groups that Report Working with the CompanyBusiness Wire • 05/13/21
Horizon Therapeutics plc to Present at the Bank of America Securities 2021 Health Care ConferenceBusiness Wire • 05/06/21
New Analysis of UPLIZNA® (inebilizumab-cdon) for Neuromyelitis Optica Spectrum Disorder (NMOSD) Published in Neurology Neuroimmunology & NeuroinflammationBusiness Wire • 05/06/21
Horizon Therapeutics plc Announces Elizabeth H.Z. Thompson as a Healthcare Businesswomen's Association 2021 LuminaryBusiness Wire • 05/06/21
Horizon Therapeutics' (HZNP) CEO Tim Walbert on Q1 2021 Results - Earnings Call TranscriptSeeking Alpha • 05/05/21
Horizon Stock Dives As Guidance Boost Fails To Overcome Sales MissInvestors Business Daily • 05/05/21
Horizon Therapeutics plc Reports First-Quarter 2021 Financial Results; Updating Full-Year 2021 Net Sales Guidance and Full-Year Adjusted EBITDA Guidance to Incorporate Recently Acquired Viela Bio, Inc.Business Wire • 05/05/21
Horizon Therapeutics plc Ranks Among the Top Companies in Overall Corporate Reputation in 2020 PatientView Survey of Patient Organizations WorldwideBusiness Wire • 04/27/21
HemoShear Therapeutics Advances Second Novel Drug Target into Horizon Therapeutics plc Early Discovery Pipeline for GoutPRNewsWire • 04/21/21
Earnings Season Preview: Horizon Pharma Near Buy Zone With EPS DueInvestors Business Daily • 04/21/21
Forbion Announces Final Close of Forbion Growth Opportunities Fund I at EUR 360 Million (USD 428 Million)Business Wire • 04/20/21
New Long-Term Data for UPLIZNA® (inebilizumab-cdon) in People Living with Neuromyelitis Optica Spectrum Disorder (NMOSD)Business Wire • 04/16/21
New Integrated Data and Follow-up Outcomes From Two TEPEZZA® (teprotumumab-trbw) Pivotal Trials Published in The Lancet Diabetes & EndocrinologyBusiness Wire • 04/16/21
Horizon Therapeutics plc to Release First-Quarter 2021 Financial Results and Host Webcast on May 5, 2021Business Wire • 04/08/21